Financial Data and Key Metrics Changes - In Q4 2025, Adjusted EBITDA increased by $2.2 million or 17.1% to $15.2 million compared to $13 million in Q4 2024 [4] - Q4 revenue was $90.9 million, a 4% decrease from the prior year, but excluding flight equipment sales, revenue increased by 9.8% [4][5] - For the full year 2025, total revenue was $335.3 million, a decrease of $9.8 million or 2.8% year-over-year, primarily due to fewer flight equipment sales [6] - Full year Adjusted EBITDA increased by $12.8 million to $46.1 million, up 38.2% year-over-year [7][18] Business Line Data and Key Metrics Changes - Asset Management revenue in Q4 declined approximately 11.1% year-over-year to $56.9 million due to fewer flight equipment sales [14] - Excluding flight equipment sales, Asset Management segment revenue increased by 47.3% for the full year, supported by strong inventory levels and demand [15] - TechOps revenue in Q4 increased by 10.7% to $34 million, driven by higher sales in aerostructures and landing gear MROs [15] - For the full year, TechOps revenue declined by 4.5% to $123.7 million, primarily due to lower on-airport MRO activity, but gross margin improved to 25.6% from 16.6% [16] Market Data and Key Metrics Changes - The company ended 2025 with $364 million of inventory, including approximately $150 million ready for deployment in the USM channel [28] - The win rate for feedstock acquisition was 4.8% in Q4 2025, down from 17.2% in Q4 2024, indicating a hyper-competitive market [7][8] Company Strategy and Development Direction - The company aims to mitigate earnings volatility by growing more recurring and predictable parts of the business, including expanding USM sales and leasing [11] - Strategic adjustments in MRO facilities are expected to contribute significantly to profitability in 2026 [9] - The company is focused on marketing its Enhanced Flight Vision System, AerAware, to both commercial and governmental customers [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving substantial growth in 2026, supported by efficiency initiatives and a strong balance sheet [12][19] - The company anticipates steady incremental improvements as new revenue streams ramp up and efficiency initiatives continue to gain traction [19] Other Important Information - The company received FAA approval to overhaul Boeing 737 MAX and 787 landing gear, expanding its capabilities [10] - The AerSafe product line is expected to see significant sales in 2026 due to compliance deadlines, with a backlog already exceeding last year's total sales [48] Q&A Session Summary Question: Feedstock acquisition goals and inventory monetization - Management anticipates a lower level of feedstock purchases in 2026 compared to 2025 due to a hyper-competitive market [22][23] - The company has ample inventory to support growth without needing to purchase as much feedstock as last year [27][28] Question: Impact of GTF normalization and AerSafe deadline - Management does not expect GTF normalization in 2026, as engine returns are anticipated to extend into 2027 [31] - AerSafe sales are expected to peak in 2026, with ongoing efforts to develop new engineered products to maintain revenue [49]

Omada Health (NasdaqGS:OMDA) Q4 2025 Earnings call March 05, 2026 04:30 PM ET Company ParticipantsAllan Kells - VP Investor of RelationsCraig Hettenbach - Managing DirectorDavid Roman - Managing DirectorElizabeth Anderson - Senior Managing DirectorRichard Close - Managing Director of Digital and Tech-Enabled Health Equity ResearchSean Duffy - Co-founder and CEOSteve Cook - CFOWei-Li Shao - PresidentConference Call ParticipantsCarly Becker - AnalystRyan MacDonald - Managing Director and Senior Equity Researc ...

Gevo (NasdaqCM:GEVO) Q4 2025 Earnings call March 05, 2026 04:30 PM ET Company ParticipantsChris Ryan - President and COODerrick Whitfield - Managing DirectorDushyant Ailani - SVP of Equity ResearchEric Frey - VP of Finance and StrategyLeke Agiri - CFOPatrick Gruber - CEOPaul Bloom - PresidentPeter Gastreich - Managing Director of Energy Transition and Sustainable InvestingConference Call ParticipantsJeff Grampp - Managing Director and Senior Research AnalystSameer Joshi - Senior Equity Research AnalystOpera ...

Owlet (NYSE:OWLT) Q4 2025 Earnings call March 05, 2026 04:30 PM ET Company ParticipantsAmanda Twede Crawford - CFOJay Gentzkow - Head of Investor RelationsJonathan Harris - President and CEOConference Call ParticipantsAndrew Brackmann - Healthcare Research AnalystIan Arndt - AnalystJonna Kim - VP of Consumer - Apparel, Footwear & Textiles Retailing and Specialty Stores Research AnalystOwen Rickert - VP and Senior Research AnalystOperatorGood afternoon. Thank you for attending the Owlet Q4 and full year 2025 ...

Financial Data and Key Metrics Changes - Fourth quarter revenues were $13.2 million, representing a 60% increase year-over-year, while full-year revenues were $45.2 million, reflecting a 53% increase compared to the previous year [6][26] - Gross margin for the fourth quarter improved to 87% from 85% in the prior year, driven by better manufacturing efficiency [24] - Net operating loss for the quarter was $3.3 million, a significant decrease from $7.6 million in the prior year [25] - Adjusted EBITDA loss for the quarter was approximately $950,000, an improvement from a loss of $5.7 million in the prior year [25] Business Line Data and Key Metrics Changes - Revenue from the TriNav system for the full year was $45 million, a 53% increase compared to the previous year, primarily driven by increased sales in liver-directed therapies [26] - Research and development expenses decreased by $2.7 million for the year, mainly due to the closeout of clinical trial expenses related to nelitolimod [27] - Sales and marketing expenses increased by $2.9 million for the year, attributed to higher performance-related compensation due to increased sales [28] Market Data and Key Metrics Changes - The total addressable market for liver embolization procedures is approximately $480 million, while the broader embolization market, including thyroid and uterine artery embolization, represents a $2.3 billion opportunity [15][16] - The introduction of the CMS HCPCS code C8004 expanded coverage for simulation or mapping procedures using TriNav, effectively doubling the reimbursable use of the technology [16] Company Strategy and Development Direction - The primary strategic priority is to expand sales and commercial infrastructure, with plans to nearly double the commercial footprint [9][10] - The company is investing in foundational clinical studies to validate the Pressure-Enabled Drug Delivery (PEDD) platform, which is expected to drive growth in 2027 and beyond [9] - The product portfolio is expanding from two core products at the beginning of 2025 to seven differentiated offerings by 2026, enhancing sales productivity [12] Management's Comments on Operating Environment and Future Outlook - Management reaffirmed revenue guidance for 2026 in the range of $60 million to $62 million, with growth expected to be weighted towards the second half of the year [9][22] - The company anticipates that the significant investment in the sales force will lead to stronger productivity and revenue growth exiting 2026 [10] - Management emphasized the importance of clinical data releases in driving adoption of new applications, particularly in non-liver areas [33][60] Other Important Information - The company raised $46 million in gross proceeds through a public offering, which was oversubscribed and supported by experienced healthcare investors [8][30] - The company is awaiting FDA clearance for the TriNav Advance product, which is expected to enhance therapeutic delivery and expand market opportunities [15][49] Q&A Session Summary Question: Contribution to growth in 2026 from liver versus non-liver - Management indicated that liver will still be the majority of revenue in 2026, but expects meaningful progress in new applications tied to data releases in the second half of the year [33] Question: Balancing growth cadence and EBITDA pathway - Management is not providing specific timing on cash flow or adjusted EBITDA breakeven but is focused on investments to scale the company meaningfully [34][35] Question: Details on the sales organization structure after investments - Management confirmed that the commercial organization will be significantly expanded, including adding a layer of management to improve sales effectiveness [39][40] Question: Growth expectations for mapping and simulation - Management expressed confidence in growth from TriNav XP and TriNav Advance, which are expected to enhance mapping capabilities [46][48] Question: Use patterns for the TriNav product portfolio - Management noted varied use patterns among physicians, with some preferring specific products while others seek access to the full portfolio for clinical flexibility [52][56] Question: Long-term opportunities for TriNav in liver versus non-liver - Management highlighted that liver will remain a significant component of sales, but sees substantial growth potential in thyroid artery embolization and other new applications [60][62]

Full House Resorts (NasdaqCM:FLL) Q4 2025 Earnings call March 05, 2026 04:30 PM ET Company ParticipantsAdam Campbell - Corporate ControllerDaniel Lee - CEO and DirectorLewis Fanger - President, CFO, and TreasurerConference Call ParticipantsChad Beynon - Managing Director and Senior AnalystDavid Bain - Managing Director and Senior Research AnalystJohn DeCree - Managing Director and Senior AnalystJordan Bender - Director and Senior Equity Research AnalystRyan Sigdahl - Senior Research AnalystOperatorWelcome t ...

Research Frontiers (NasdaqCM:REFR) Q4 2025 Earnings call March 05, 2026 04:30 PM ET Company ParticipantsArt Grady - InvestorJeff Harvey - InvestorJoe Harary - President and CEOJohn Nelson - InvestorMichael Forster - InvestorOperatorGood afternoon. Welcome to Research Frontiers investor conference call to discuss the fourth quarter and year-end 2025 results of operations and recent developments. The company will be answering many of the questions that were emailed to it prior to this conference call, either ...

Grid Dynamics (NasdaqCM:GDYN) Q4 2025 Earnings call March 05, 2026 04:30 PM ET Company ParticipantsAnil Doradla - CFOEugene Steinberg - CTOIlya Katsov - CTO of AmericasLeonard Livschitz - CEOPuneet Jain - Associate-Equity ResearchRahul Bindlish - SVP, Global Head of Partnerships and MarketingVasily Sizov - SVP of Head of AmericasYury Gryzlov - COO and Head of EuropeConference Call ParticipantsBrian Bergen - Managing Director and Senior Equity Research AnalystMaggie Nolan - Research Analyst, Technology, Medi ...

Gevo (NasdaqCM:GEVO) Q4 2025 Earnings call March 05, 2026 04:30 PM ET Company ParticipantsChris Ryan - President and COODerrick Whitfield - Managing DirectorDushyant Ailani - SVP of Equity ResearchEric Frey - VP of Finance and StrategyLeke Agiri - CFOPatrick Gruber - CEOPaul Bloom - PresidentPeter Gastreich - Managing Director of Energy Transition and Sustainable InvestingConference Call ParticipantsJeff Grampp - Managing Director and Senior Research AnalystSameer Joshi - Senior Equity Research AnalystOpera ...

Trisalus Life Sciences (NasdaqGM:TLSI) Q4 2025 Earnings call March 05, 2026 04:30 PM ET Company ParticipantsDavid Patience - CFOJeremy Feffer - Managing Director and Relationship ManagerJon Young - DirectorJustin Walsh - Director of Healthcare Equity ResearchMary Szela - President and CEORichard Marshall - Medical DirectorConference Call ParticipantsFrank Takkinen - Senior Research AnalystOperatorDay, welcome to the TriSalus Life Sciences Fourth Quarter 2025 Earnings Call. At this time, all participants are ...